National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic : Version 1
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved..
OBJECTIVE: To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic.
STUDY DESIGN: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.
RESULTS: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus.
LIMITATIONS: The evidence behind many guidance statements is limited in quality.
CONCLUSION: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Journal of the American Academy of Dermatology - 83(2020), 6 vom: 30. Dez., Seite 1704-1716 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gelfand, Joel M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biologics |
|---|
| Anmerkungen: |
Date Completed 01.12.2020 Date Revised 15.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaad.2020.09.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314645322 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314645322 | ||
| 003 | DE-627 | ||
| 005 | 20231225153157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaad.2020.09.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM314645322 | ||
| 035 | |a (NLM)32891785 | ||
| 035 | |a (PII)S0190-9622(20)32544-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gelfand, Joel M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic |b Version 1 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2020 | ||
| 500 | |a Date Revised 15.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic | ||
| 520 | |a STUDY DESIGN: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted | ||
| 520 | |a RESULTS: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus | ||
| 520 | |a LIMITATIONS: The evidence behind many guidance statements is limited in quality | ||
| 520 | |a CONCLUSION: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a psoriasis | |
| 650 | 4 | |a psoriatic arthritis | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Armstrong, April W |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, Stacie |e verfasserin |4 aut | |
| 700 | 1 | |a Anesi, George L |e verfasserin |4 aut | |
| 700 | 1 | |a Blauvelt, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrese, Cassandra |e verfasserin |4 aut | |
| 700 | 1 | |a Dommasch, Erica D |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Steve R |e verfasserin |4 aut | |
| 700 | 1 | |a Gladman, Dafna |e verfasserin |4 aut | |
| 700 | 1 | |a Kircik, Leon |e verfasserin |4 aut | |
| 700 | 1 | |a Lebwohl, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Lo Re, Vincent |c 3rd |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, George |e verfasserin |4 aut | |
| 700 | 1 | |a Merola, Joseph F |e verfasserin |4 aut | |
| 700 | 1 | |a Scher, Jose U |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartzman, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Treat, James R |e verfasserin |4 aut | |
| 700 | 1 | |a Van Voorhees, Abby S |e verfasserin |4 aut | |
| 700 | 1 | |a Ellebrecht, Christoph T |e verfasserin |4 aut | |
| 700 | 1 | |a Fenner, Justine |e verfasserin |4 aut | |
| 700 | 1 | |a Ocon, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Syed, Maha N |e verfasserin |4 aut | |
| 700 | 1 | |a Weinstein, Erica J |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Gondo, George |e verfasserin |4 aut | |
| 700 | 1 | |a Heydon, Sue |e verfasserin |4 aut | |
| 700 | 1 | |a Koons, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Ritchlin, Christopher T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Academy of Dermatology |d 1984 |g 83(2020), 6 vom: 30. Dez., Seite 1704-1716 |w (DE-627)NLM000422703 |x 1097-6787 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2020 |g number:6 |g day:30 |g month:12 |g pages:1704-1716 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaad.2020.09.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2020 |e 6 |b 30 |c 12 |h 1704-1716 | ||